12 January 2022 | News
The solution would be based on disruptive 4D Bioprinting technology
Image Credit: Shutterstock
Alkem Laboratories has announced to launch a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval.
Alkem has collaborated with South Korea-based Rokit Healthcare to commercialise the technology in India.
The advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India.